A Phase 2 Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Multi-Dose Study To Investigate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of RN6G (PF-04382923) In Subjects With Geographic Atrophy Secondary To Age-Related Macular Degeneration

Trial Profile

A Phase 2 Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Multi-Dose Study To Investigate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of RN6G (PF-04382923) In Subjects With Geographic Atrophy Secondary To Age-Related Macular Degeneration

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2016

At a glance

  • Drugs PF 4382923 (Primary)
  • Indications Age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 06 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top